Drug
Nnc0642 1895
Nnc0642 1895: highest development phase Phase 1, developed by Novo Nordisk. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| NNC0642-1895 NCT07829406 | Phase 1 |
Latest
No recent events.
Follow Nnc0642 1895 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.